Last reviewed · How we verify
Genprex, Inc. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Platinum-Based Chemotherapy | Platinum-Based Chemotherapy | marketed | Platinum-based alkylating agent | DNA | Oncology |
Therapeutic area mix
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Bristol-Myers Squibb · 1 shared drug class
- Cedars-Sinai Medical Center · 1 shared drug class
- Insel Gruppe AG, University Hospital Bern · 1 shared drug class
- Ming-Yuan Chen · 1 shared drug class
- Peking University Third Hospital · 1 shared drug class
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 1 shared drug class
- Sun Yat-sen University · 1 shared drug class
- Tata Memorial Hospital · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Genprex, Inc.:
- Genprex, Inc. pipeline updates — RSS
- Genprex, Inc. pipeline updates — Atom
- Genprex, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Genprex, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/genprex-inc. Accessed 2026-05-14.